This Government Contract opportunity from Department Of Health And Human Services was posted on July 5, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
Notice of Intent to Award a Sole Source Commercial Simplified Acquisition Procedures (SAP) Contract for Development of a Human Neural Network Formation New Approach Method for the Evaluation of Potential Developmental Neurotoxicity
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The Food and Drug Administration intends to award a sole source firm-fixed price contract to Cyprotex US, LLC for the development of a human neural network formation new approach method to evaluate potential developmental neurotoxicity, utilizing microelectrode array technology that meets the agency’s specific needs and for which no other vendor offers a comparable solution. This acquisition, conducted under simplified acquisition procedures for commercial services and authorized under FAR Part 6.302-1, follows the North American Industry Classification System code 541690 and is not open for competitive bidding. The sole source determination is based on Cyprotex US, LLC’s exclusive capability to deliver the required neural network formation NAM tailored to FDA’s requirements. The primary deliverable is raw experimental data in electronic format, such as .csv or .RData files, with an estimated delivery date of January 31, 2027. Responses to this notice, which is not a solicitation for competitive quotes, must be submitted by July 10, 2026, to Haroon Gulzar at haroon.gulzar@fda.hhs.gov. Any other firms wishing to be considered must provide a detailed capability statement demonstrating they can meet the requirement, though the government retains full discretion to determine whether to proceed without competition. The contract will be performed at Cyprotex’s facility in Framingham, Massachusetts, and administered by the FDA Office of Acquisition and Grant Services in Rockville, Maryland.
General Info
Agency
NAICS
Place of Performance
Framingham, MA, USASet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Submission Closed
Organization & Contact Information
Full Description
The Food and Drug Administration (FDA) intends to award a Sole Source firm-fixed price contract to Cyprotex US, LLC, 200 Staples Drive, Framingham, MA 01702, USA, incorporated for the purchase of Development of a Human Neural Network Formation New Approach Method for the Evaluation of Potential Developmental Neurotoxicity, in accordance with the authority under FAR Part 6.302-1. Only one responsible source and no other supplies or services will satisfy agency requirements.
Cyprotex US, LLC is qualified for DT/OCT/OLOAS/HFP unique requirement because they are the only vendor that offers a neural network formation NAM which utilizes microelectrode array (MEA) technology that can be appropriately adapted for the agency specific needs.
This acquisition is being conducted using simplified acquisition procedures in accordance with FAR RFO Part 12 for the acquisition of commercial products and commercial services.
The North American Industry Classification System (NAICS) code for the proposed acquisition is 541690 - Other Scientific and Technical Consulting Services.
Deliverables
Raw experimental data, noting any deviations from standard procedure - Electronic file (.csv or .RData preferred) - Estimated Delivery Date - 01/31/27
Responses
Responses to this notice should be sent to Haroon Gulzar at haroon.gulzar@fda.hhs.gov no later than 5:00 pm (ET) on July 10, 2026. This notice is not a request for competitive quotes. Any other firms desiring consideration must fully identify their interest and capability of meeting the requirements by submitting a capability statement. Any response shall undergo review to determine if it can meet the requirements. A determination by the Government not to compete this proposed requirement based upon a response to this notice is solely within the discretion of the Government.
More opportunities from Department Of Health And Human Services → FDA Office Of Acq Grant Svcs
Same awarding agency
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS
